Metabolomics in hepatocellular carcinoma: From biomarker discovery to precision medicine

Hepatocellular carcinoma (HCC) remains a global health burden, and is mostly diagnosed at late and advanced stages. Currently, limited and insensitive diagnostic modalities continue to be the bottleneck of effective and tailored therapy for HCC patients. Moreover, the complex reprogramming of metabo...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in medical technology Vol. 4; p. 1065506
Main Authors Wu, Xingyun, Wang, Zihao, Luo, Li, Shu, Dan, Wang, Kui
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 04.01.2023
Subjects
biomarkers
hepatocellular carcinoma
Medical Technology
metabolomics
multi-omics
precision medicine
multi-omics
precision medicine
metabolomics
biomarkers
hepatocellular carcinoma
Online AccessGet full text
ISSN2673-3129
2673-3129
DOI10.3389/fmedt.2022.1065506

Cover

Abstract Hepatocellular carcinoma (HCC) remains a global health burden, and is mostly diagnosed at late and advanced stages. Currently, limited and insensitive diagnostic modalities continue to be the bottleneck of effective and tailored therapy for HCC patients. Moreover, the complex reprogramming of metabolic patterns during HCC initiation and progression has been obstructing the precision medicine in clinical practice. As a noninvasive and global screening approach, metabolomics serves as a powerful tool to dynamically monitor metabolic patterns and identify promising metabolite biomarkers, therefore holds a great potential for the development of tailored therapy for HCC patients. In this review, we summarize the recent advances in HCC metabolomics studies, including metabolic alterations associated with HCC progression, as well as novel metabolite biomarkers for HCC diagnosis, monitor, and prognostic evaluation. Moreover, we highlight the application of multi-omics strategies containing metabolomics in biomarker discovery for HCC. Notably, we also discuss the opportunities and challenges of metabolomics in nowadays HCC precision medicine. As technologies improving and metabolite biomarkers discovering, metabolomics has made a major step toward more timely and effective precision medicine for HCC patients.
AbstractList Hepatocellular carcinoma (HCC) remains a global health burden, and is mostly diagnosed at late and advanced stages. Currently, limited and insensitive diagnostic modalities continue to be the bottleneck of effective and tailored therapy for HCC patients. Moreover, the complex reprogramming of metabolic patterns during HCC initiation and progression has been obstructing the precision medicine in clinical practice. As a noninvasive and global screening approach, metabolomics serves as a powerful tool to dynamically monitor metabolic patterns and identify promising metabolite biomarkers, therefore holds a great potential for the development of tailored therapy for HCC patients. In this review, we summarize the recent advances in HCC metabolomics studies, including metabolic alterations associated with HCC progression, as well as novel metabolite biomarkers for HCC diagnosis, monitor, and prognostic evaluation. Moreover, we highlight the application of multi-omics strategies containing metabolomics in biomarker discovery for HCC. Notably, we also discuss the opportunities and challenges of metabolomics in nowadays HCC precision medicine. As technologies improving and metabolite biomarkers discovering, metabolomics has made a major step toward more timely and effective precision medicine for HCC patients.
Hepatocellular carcinoma (HCC) remains a global health burden, and is mostly diagnosed at late and advanced stages. Currently, limited and insensitive diagnostic modalities continue to be the bottleneck of effective and tailored therapy for HCC patients. Moreover, the complex reprogramming of metabolic patterns during HCC initiation and progression has been obstructing the precision medicine in clinical practice. As a noninvasive and global screening approach, metabolomics serves as a powerful tool to dynamically monitor metabolic patterns and identify promising metabolite biomarkers, therefore holds a great potential for the development of tailored therapy for HCC patients. In this review, we summarize the recent advances in HCC metabolomics studies, including metabolic alterations associated with HCC progression, as well as novel metabolite biomarkers for HCC diagnosis, monitor, and prognostic evaluation. Moreover, we highlight the application of multi-omics strategies containing metabolomics in biomarker discovery for HCC. Notably, we also discuss the opportunities and challenges of metabolomics in nowadays HCC precision medicine. As technologies improving and metabolite biomarkers discovering, metabolomics has made a major step toward more timely and effective precision medicine for HCC patients.Hepatocellular carcinoma (HCC) remains a global health burden, and is mostly diagnosed at late and advanced stages. Currently, limited and insensitive diagnostic modalities continue to be the bottleneck of effective and tailored therapy for HCC patients. Moreover, the complex reprogramming of metabolic patterns during HCC initiation and progression has been obstructing the precision medicine in clinical practice. As a noninvasive and global screening approach, metabolomics serves as a powerful tool to dynamically monitor metabolic patterns and identify promising metabolite biomarkers, therefore holds a great potential for the development of tailored therapy for HCC patients. In this review, we summarize the recent advances in HCC metabolomics studies, including metabolic alterations associated with HCC progression, as well as novel metabolite biomarkers for HCC diagnosis, monitor, and prognostic evaluation. Moreover, we highlight the application of multi-omics strategies containing metabolomics in biomarker discovery for HCC. Notably, we also discuss the opportunities and challenges of metabolomics in nowadays HCC precision medicine. As technologies improving and metabolite biomarkers discovering, metabolomics has made a major step toward more timely and effective precision medicine for HCC patients.
Author Wang, Zihao
Wang, Kui
Shu, Dan
Wu, Xingyun
Luo, Li
AuthorAffiliation 4 Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University) , Ministry of Education , Chengdu , China
5 School of Bioscience and Technology , Chengdu Medical College , Chengdu , China
3 Center for Reproductive Medicine, Department of Gynecology and Obstetrics , West China Second University Hospital, Sichuan University , Chengdu , China
1 West China School of Basic Medical Science & Forensic Medicine , Sichuan University , Chengdu , China
2 Department of Gastrointestinal Surgery , West China Hospital, Sichuan University , Chengdu , China
AuthorAffiliation_xml – name: 5 School of Bioscience and Technology , Chengdu Medical College , Chengdu , China
– name: 1 West China School of Basic Medical Science & Forensic Medicine , Sichuan University , Chengdu , China
– name: 3 Center for Reproductive Medicine, Department of Gynecology and Obstetrics , West China Second University Hospital, Sichuan University , Chengdu , China
– name: 4 Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University) , Ministry of Education , Chengdu , China
– name: 2 Department of Gastrointestinal Surgery , West China Hospital, Sichuan University , Chengdu , China
Author_xml – sequence: 1
  givenname: Xingyun
  surname: Wu
  fullname: Wu, Xingyun
– sequence: 2
  givenname: Zihao
  surname: Wang
  fullname: Wang, Zihao
– sequence: 3
  givenname: Li
  surname: Luo
  fullname: Luo, Li
– sequence: 4
  givenname: Dan
  surname: Shu
  fullname: Shu, Dan
– sequence: 5
  givenname: Kui
  surname: Wang
  fullname: Wang, Kui
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36688143$$D View this record in MEDLINE/PubMed
BookMark eNp9Uk1vFSEUJabG1to_4MLM0s17XmDggQsT01htUuNGE3cEmEtLnRmewGvSfy_vw6Z14YobOOfcw73nJTma04yEvKaw5Fzpd2HCoS4ZMLakIIUA-YycMLniC06ZPnpUH5OzUm4BgAnKGO9fkGMupVK05yfk51es1qUxTdGXLs7dDa5tTR7HcTPa3HmbfZzTZN93FzlNnYutzr8wd0MsPt1hvu9q6tYZfSwxzV2zFRsDX5HnwY4Fzw7nKflx8en7-ZfF1bfPl-cfrxa-l6ounAgOFGivuUAnpLAAwwCecgiUKa2ospqzldaDWCnmUPdWqt5z6FVAEfgpudzrDsnemnWOzd69STaa3UXK18bmGv2IBgIoF7SnjrneArNBo1KSaU19cLjV-rDXWm9c-4fHuWY7PhF9-jLHG3Od7oxWvdCCN4G3B4Gcfm-wVDO1KbVZ2hnTphi22s1dQt-gbx73emjydzUNwPYAn1MpGcMDhILZRsDsImC2ETCHCDSS-ofkY7W1Lab5jeP_qH8A7mK43A
CitedBy_id crossref_primary_10_3390_cancers17050844
crossref_primary_10_1007_s12032_024_02538_8
crossref_primary_10_1016_j_intimp_2024_112813
crossref_primary_10_1038_s41467_023_36708_5
crossref_primary_10_1016_j_biopha_2023_116021
crossref_primary_10_1038_s41598_024_70752_5
crossref_primary_10_1021_acs_analchem_4c03256
crossref_primary_10_4254_wjh_v15_i11_1237
crossref_primary_10_7759_cureus_72239
crossref_primary_10_1186_s12935_023_03027_0
crossref_primary_10_1002_smll_202410638
crossref_primary_10_1016_j_cca_2023_117302
crossref_primary_10_1186_s12967_023_04801_4
crossref_primary_10_3390_metabo13101047
crossref_primary_10_1016_j_cytogfr_2024_08_006
crossref_primary_10_3390_cancers15184527
crossref_primary_10_3390_ijms252111847
crossref_primary_10_1089_adt_2025_015
Cites_doi 10.3390/cancers11101497
10.1038/srep12757
10.1158/0008-5472.CAN-11-0885
10.1016/j.clinre.2015.12.007
10.1038/srep18175
10.1021/acs.jproteome.5b01032
10.1053/j.gastro.2011.12.061
10.1074/mcp.RA118.000586
10.1038/s41572-020-00240-3
10.3389/fonc.2022.822449
10.3390/molecules26144111
10.1021/ac0517085
10.1038/srep41089
10.18632/oncotarget.11521
10.1021/acs.analchem.7b00660
10.1016/j.tips.2016.10.012
10.1136/gutjnl-2021-325189
10.1038/nrd.2016.32
10.1016/j.ab.2009.12.006
10.1046/j.1365-313x.2000.00774.x
10.1016/j.jcf.2017.10.013
10.3390/ht7020009
10.1053/j.gastro.2009.04.005
10.1158/1055-9965.EPI-16-0366
10.4253/wjge.v10.i2.56
10.4103/jcar.JCar_9_16
10.1074/mcp.M111.010694
10.1002/hep.29561
10.1007/s11306-018-1397-x
10.1002/mc.23455
10.1007/s11306-019-1619-x
10.3390/metabo2040701
10.1016/j.aca.2012.07.013
10.1021/ac8022857
10.1002/jssc.201900736
10.1007/s00216-021-03768-9
10.1111/j.1365-2036.2009.04014.x
10.1146/annurev-biochem-061516-044952
10.1016/j.ejps.2017.05.018
10.1158/0008-5472.CAN-15-3199
10.1002/mas.21445
10.4155/bio.14.236
10.1016/j.aca.2013.04.017
10.3390/cancers14010231
10.1002/hep.29086
10.1021/acsomega.0c04259
10.1016/j.aca.2009.06.033
10.1021/ac403672u
10.1007/s11306-010-0219-6
10.1021/pr500390y
10.1194/jlr.M092643
10.3390/jpm12020149
10.1038/nrm.2016.25
10.1159/000509424
10.1053/j.gastro.2013.01.054
10.1200/JCO.2016.67.1222
10.1016/j.jhep.2017.09.016
10.3390/cancers13194981
10.1021/pr400204q
10.1038/s41575-019-0186-y
10.1002/jms.659
10.1038/nrgastro.2016.193
10.1158/1078-0432.CCR-12-1099
10.1053/j.gastro.2018.01.064
10.1021/pr500973d
10.1016/j.ejso.2015.04.023
10.2147/JHC.S370255
10.1038/srep16101
10.1002/ijc.28706
10.18632/oncotarget.23500
10.1002/ijc.32599
10.1016/s0140-6736(18)30010-2
10.1016/j.copbio.2016.08.001
10.3390/metabo10080314
10.3748/wjg.v26.i31.4607
10.1158/1940-6207.CAPR-17-0249
10.1016/j.ejso.2019.07.004
10.1371/journal.pone.0127299
10.1039/C8MO00126J
10.1002/mas.21548
10.4155/bio.12.14
10.1021/pr300673x
10.1002/ijc.34229
10.1007/s13277-010-0116-7
10.1126/science.2675315
10.3390/metabo11010054
10.1016/j.cell.2017.09.019
10.18632/oncotarget.4202
10.3390/ijms231911975
10.3748/wjg.v25.i19.2279
10.3390/cancers12010241
10.1002/mas.21455
10.1186/s12916-015-0462-9
10.1007/s00216-012-6117-1
10.3390/ijms20010139
10.3390/ijms22094495
10.1016/j.cca.2018.10.039
10.3322/caac.21670
10.1016/j.jfda.2019.10.003
10.1021/ac0522299
10.1158/0008-5472.CAN-13-0308
10.1002/hep.26350
10.18632/oncotarget.10119
10.1016/0092-8674(90)90076-Q
10.1016/j.cld.2020.07.013
10.3171/jns.2002.96.6.1023
10.5114/ceh.2019.89478
10.1016/j.urolonc.2011.05.013
10.1002/mas.21439
10.3322/caac.21492
10.1016/j.bbcan.2018.04.009
10.1002/hep.21467
10.1111/liv.12541
10.1016/j.cmet.2019.08.024
10.1021/acs.jproteome.0c00344
10.1021/tx0255774
10.1016/j.jlr.2021.100143
10.3390/cancers13112787
10.3390/ijms20194781
10.3390/cancers11121906
ContentType Journal Article
Copyright 2023 Wu, Wang, Luo, Shu and Wang.
2023 Wu, Wang, Luo, Shu and Wang. 2023 Wu, Wang, Luo, Shu and Wang
Copyright_xml – notice: 2023 Wu, Wang, Luo, Shu and Wang.
– notice: 2023 Wu, Wang, Luo, Shu and Wang. 2023 Wu, Wang, Luo, Shu and Wang
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fmedt.2022.1065506
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 2673-3129
ExternalDocumentID oai_doaj_org_article_0f08bf9c1b2b4a02af9e8862991cfbef
PMC9845953
36688143
10_3389_fmedt_2022_1065506
Genre Journal Article
Review
GrantInformation_xml – fundername: ;
  grantid: ZYYC21001
– fundername: ;
  grantid: 81872277, 81821002, 81790251, 82073081, 82002963, 82273122
– fundername: Guangdong Basic and Applied Basic Research Foundation
  grantid: 2019B030302012
GroupedDBID 9T4
AAFWJ
AAYXX
ACXDI
AFPKN
ALMA_UNASSIGNED_HOLDINGS
CITATION
GROUPED_DOAJ
M~E
OK1
PGMZT
RPM
NPM
7X8
5PM
ID FETCH-LOGICAL-c468t-b5fb0809c935eb565a00dd0c130f1289818a932799d5782be94a684c3048fe5f3
IEDL.DBID DOA
ISSN 2673-3129
IngestDate Wed Aug 27 01:26:20 EDT 2025
Thu Aug 21 18:39:11 EDT 2025
Fri Jul 11 12:32:49 EDT 2025
Thu Jan 02 22:55:29 EST 2025
Thu Apr 24 22:59:11 EDT 2025
Tue Jul 01 04:18:30 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords multi-omics
precision medicine
metabolomics
biomarkers
hepatocellular carcinoma
Language English
License 2023 Wu, Wang, Luo, Shu and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c468t-b5fb0809c935eb565a00dd0c130f1289818a932799d5782be94a684c3048fe5f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Abbreviations HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, non-alcoholic fatty liver disease; AFP, α-fetoprotein; NMR, nuclear magnetic resonance; MS, mass spectrometry; DEN, diethyl-nitrosamine; GC, gas chromatography; LC, liquid chromatography; CE, capillary electrophoresis; FFA, free fatty acid; ESI, electrospray ionization; FT-ICR, Fourier transform ion cyclotron resonance; TOF, time of flight; Q, quadrupole; SRM, selected reaction monitoring; MRM, multiple reaction monitoring; PCA, principal component analysis; PLS-DA, partial least squares regression discriminant analysis; OPLS, orthogonal partial last squares; ROC, receiver operating characteristic; NFSM, network-based feature selection method; UPLC, ultra-performance liquid chromatographic; LASSO, least absolute shrinkage and selection operator; TACE, transcatheter arterial chemoembolization; RFA, radiofrequency ablation; UGPase 2, uridine diphosphate glucose pyrophosphorylase 2; TP53, tumor protein p53; TCF1, transcription factor 1; SCD, stearoyl-CoA-desaturase; HBc, hepatitis B virus core protein; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes pathway.
Edited by: Chon Lok Lei, University of Macau, China
Specialty Section: This article was submitted to Medtech Data Analytics, a section of the journal Frontiers in Medical Technology
These authors have contributed equally to this work and share first authorship
Reviewed by: Xuefeng Li, University of Texas MD Anderson Cancer Center, United States Xiaonan Zheng, University of Oxford, United Kingdom
OpenAccessLink https://doaj.org/article/0f08bf9c1b2b4a02af9e8862991cfbef
PMID 36688143
PQID 2768814604
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_0f08bf9c1b2b4a02af9e8862991cfbef
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9845953
proquest_miscellaneous_2768814604
pubmed_primary_36688143
crossref_primary_10_3389_fmedt_2022_1065506
crossref_citationtrail_10_3389_fmedt_2022_1065506
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-01-04
PublicationDateYYYYMMDD 2023-01-04
PublicationDate_xml – month: 01
  year: 2023
  text: 2023-01-04
  day: 04
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in medical technology
PublicationTitleAlternate Front Med Technol
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Galun (B6) 2022; 12
Ghouri (B3) 2017; 16
Roberts (B72) 2018; 17
Nomair (B91) 2019; 5
Marrero (B13) 2020; 24
Zhou (B78) 2020; 26
Keun (B47) 2002; 15
Fornari (B41) 2019; 11
Baumstark (B49) 2019; 60
Zhao (B36) 2017; 89
Zhu (B85) 2016; 40
Tan (B40) 2012; 11
Wang (B38) 2022; 414
Ogunwobi (B4) 2019; 25
Casadei-Gardini (B83) 2020; 12
Singal (B17) 2009; 30
Zhang (B45) 2016; 7
Li (B114) 2018; 17
Bray (B1) 2018; 68
Fages (B84) 2015; 13
Lu (B104) 2019; 45
Bingol (B66) 2018; 7
Chen (B27) 2022; 12
Buchard (B109) 2021; 11
El Rammouz (B31) 2010; 398
Khamis (B71) 2017; 36
Olivier (B26) 2019; 20
Hang (B82) 2022; 151
Mei (B121) 2022; 9
Wang (B63) 2020; 19
Lutz (B76) 2006; 78
Campbell (B70) 2012; 4
Kohler (B28) 2017
Santoni-Rugiu (B43) 1996; 149
Kang (B48) 2019; 20
El-Serag (B5) 2012; 142
Liu (B9) 2022
Di Poto (B99) 2017; 26
Hou (B115) 2022; 61
Tzartzeva (B79) 2018; 154
Pan (B88) 2021; 6
Chen (B19) 2016; 7
Mirnaghi (B59) 2014; 6
Oliveira (B67) 2014; 86
Faubert (B54) 2017; 171
Choi (B51) 2016; 34
Wu (B56) 2009; 648
Zhou (B77) 2018; 14
Yang (B8) 2019; 16
Luo (B94) 2018; 67
Nie (B113) 2016; 35
Zeng (B39) 2015; 5
Jee (B81) 2018; 11
Hopfgartner (B69) 2004; 39
Kim (B95) 2019; 11
Granlund (B53) 2020; 31
Lu (B111) 2016; 76
Ganti (B35) 2011; 29
Jhappan (B44) 1990; 61
Budhu (B118) 2013; 144
Liu (B97) 2014; 135
Zhang (B32) 2012; 404
Xia (B75) 2019; 15
Ivanisevic (B34) 2015; 5
Johnson (B29) 2016; 17
Koek (B65) 2011; 7
Beyoğlu (B117) 2013; 58
Büscher (B62) 2009; 81
Wei (B89) 2012; 2
Roessner (B58) 2000; 23
Kaushik (B25) 2018; 1870
Nahon (B100) 2012; 18
Xie (B119) 2017; 7
Chiu (B57) 2020; 28
Fitian (B90) 2014; 34
Wishart (B11) 2016; 15
Boyault (B116) 2007; 45
Dumas (B46) 2006; 78
Collins (B24) 2017; 38
Jacob (B23) 2019; 38
Wang (B110) 2011; 32
He (B42) 2015; 6
Kumar (B68) 2013; 780
Shao (B73) 2015; 14
Liu (B108) 2018; 9
Heimbach (B105) 2018; 67
Girotra (B15) 2018; 10
Sapisochin (B103) 2017; 14
Llovet (B2) 2021; 7
Njoku (B60) 2020; 10
Han (B102) 2020; 146
Goossens (B107) 2016; 15
Gao (B87) 2015; 5
Geyer (B106) 2021; 13
Kurma (B37) 2021; 13
Zhou (B14) 2020; 9
Xiao (B20) 2012; 11
Peng (B80) 2018; 14
Fang (B101) 2022; 14
Zeng (B98) 2014; 13
Abushawish (B120) 2022; 23
Fujiwara (B10) 2018; 68
Ressom (B96) 2012; 743
Noreldeen (B21) 2020; 43
Markley (B52) 2017; 43
Nezami Ranjbar (B93) 2015; 10
Chiu (B86) 2015; 41
Schmidt (B18) 2021; 71
Han (B33) 2019; 488
Courant (B74) 2013; 12
Forner (B12) 2018; 391
Martias (B22) 2021; 26
Patterson (B92) 2011; 71
Tang (B55) 2016; 35
Kim (B7) 2021; 22
Lu (B30) 2017; 86
Tzika (B50) 2002; 96
Zhang (B61) 2021; 62
Fenn (B64) 1989; 246
Marrero (B16) 2009; 137
Huang (B112) 2013; 73
References_xml – volume: 11
  year: 2019
  ident: B95
  article-title: Comprehensive metabolomic search for biomarkers to differentiate early stage hepatocellular carcinoma from cirrhosis
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers11101497
– volume: 5
  start-page: 12757
  year: 2015
  ident: B34
  article-title: Arteriovenous blood metabolomics: a readout of intra-tissue metabostasis
  publication-title: Sci Rep
  doi: 10.1038/srep12757
– volume: 71
  start-page: 6590
  year: 2011
  ident: B92
  article-title: Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-11-0885
– volume: 40
  start-page: 418
  year: 2016
  ident: B85
  article-title: Prognostic factors for survival after hepatic resection of early hepatocellular carcinoma in HBV-related cirrhotic patients
  publication-title: Clin Res Hepatol Gastroenterol
  doi: 10.1016/j.clinre.2015.12.007
– volume: 5
  start-page: 18175
  year: 2015
  ident: B87
  article-title: Serum metabolomics to identify the liver disease-specific biomarkers for the progression of hepatitis to hepatocellular carcinoma
  publication-title: Sci Rep
  doi: 10.1038/srep18175
– volume: 15
  start-page: 1446
  year: 2016
  ident: B107
  article-title: Sequential serum metabolomic profiling after radiofrequency ablation of hepatocellular carcinoma reveals different response patterns according to etiology
  publication-title: J Proteome Res
  doi: 10.1021/acs.jproteome.5b01032
– volume: 142
  start-page: 1264
  year: 2012
  ident: B5
  article-title: Epidemiology of viral hepatitis and hepatocellular carcinoma
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2011.12.061
– volume: 17
  start-page: 607
  year: 2018
  ident: B114
  article-title: Multiomics integration reveals the landscape of prometastasis metabolism in hepatocellular carcinoma
  publication-title: Mol Cell Proteomics
  doi: 10.1074/mcp.RA118.000586
– volume: 7
  start-page: 6
  year: 2021
  ident: B2
  article-title: Hepatocellular carcinoma
  publication-title: Nat Rev Dis Primers
  doi: 10.1038/s41572-020-00240-3
– volume: 12
  start-page: 822449
  year: 2022
  ident: B27
  article-title: Potential biomarkers for liver cancer diagnosis based on multi-omics strategy
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.822449
– volume: 26
  year: 2021
  ident: B22
  article-title: Optimization of sample preparation for metabolomics exploration of urine, feces, blood and saliva in humans using combined NMR and UHPLC-HRMS platforms
  publication-title: Molecules
  doi: 10.3390/molecules26144111
– volume: 78
  start-page: 2199
  year: 2006
  ident: B46
  article-title: Assessment of analytical reproducibility of 1h NMR spectroscopy based metabonomics for large-scale epidemiological research: the intermap study
  publication-title: Anal Chem
  doi: 10.1021/ac0517085
– volume: 7
  start-page: 41089
  year: 2017
  ident: B119
  article-title: Multi-omics analyses reveal metabolic alterations regulated by hepatitis B virus core protein in hepatocellular carcinoma cells
  publication-title: Sci Rep
  doi: 10.1038/srep41089
– volume: 7
  start-page: 63437
  year: 2016
  ident: B45
  article-title: Non-targeted and targeted metabolomics approaches to diagnosing lung cancer and predicting patient prognosis
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.11521
– volume: 89
  start-page: 5565
  year: 2017
  ident: B36
  article-title: High throughput and quantitative measurement of microbial metabolome by gas chromatography/mass spectrometry using automated alkyl chloroformate derivatization
  publication-title: Anal Chem
  doi: 10.1021/acs.analchem.7b00660
– volume: 38
  start-page: 25
  year: 2017
  ident: B24
  article-title: Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2016.10.012
– year: 2022
  ident: B9
  article-title: Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma
  publication-title: Gut
  doi: 10.1136/gutjnl-2021-325189
– volume: 15
  start-page: 473
  year: 2016
  ident: B11
  article-title: Emerging applications of metabolomics in drug discovery and precision medicine
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2016.32
– volume: 149
  start-page: 407
  year: 1996
  ident: B43
  article-title: Evolution of neoplastic development in the liver of transgenic mice co-expressing C-myc and transforming growth factor-alpha
  publication-title: Am J Pathol
– volume: 398
  start-page: 169
  year: 2010
  ident: B31
  article-title: Analysis of skeletal muscle metabolome: evaluation of extraction methods for targeted metabolite quantification using liquid chromatography tandem mass spectrometry
  publication-title: Anal Biochem
  doi: 10.1016/j.ab.2009.12.006
– volume: 23
  start-page: 131
  year: 2000
  ident: B58
  article-title: Technical advance: simultaneous analysis of metabolites in potato tuber by gas chromatography-mass spectrometry
  publication-title: Plant J
  doi: 10.1046/j.1365-313x.2000.00774.x
– volume: 17
  start-page: 333
  year: 2018
  ident: B72
  article-title: Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations
  publication-title: J Cyst Fibros
  doi: 10.1016/j.jcf.2017.10.013
– volume: 7
  year: 2018
  ident: B66
  article-title: Recent advances in targeted and untargeted metabolomics by NMR and MS/NMR methods
  publication-title: High Throughput
  doi: 10.3390/ht7020009
– volume: 137
  start-page: 110
  year: 2009
  ident: B16
  article-title: Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2009.04.005
– volume: 26
  start-page: 675
  year: 2017
  ident: B99
  article-title: Metabolomic characterization of hepatocellular carcinoma in patients with liver cirrhosis for biomarker discovery
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-16-0366
– volume: 10
  start-page: 56
  year: 2018
  ident: B15
  article-title: Utility of endoscopic ultrasound and endoscopy in diagnosis and management of hepatocellular carcinoma and its complications: what does endoscopic ultrasonography offer above and beyond conventional cross-sectional imaging?
  publication-title: World J Gastrointest Endosc
  doi: 10.4253/wjge.v10.i2.56
– volume: 16
  start-page: 1
  year: 2017
  ident: B3
  article-title: Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis
  publication-title: J Carcinog
  doi: 10.4103/jcar.JCar_9_16
– volume: 11
  start-page: M111.010694
  year: 2012
  ident: B40
  article-title: Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis
  publication-title: Mol Cell Proteomics
  doi: 10.1074/mcp.M111.010694
– volume: 67
  start-page: 662
  year: 2018
  ident: B94
  article-title: A large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma
  publication-title: Hepatology (Baltimore, Md)
  doi: 10.1002/hep.29561
– volume: 14
  start-page: 102
  year: 2018
  ident: B77
  article-title: Diagnosis of clostridium difficile infection using an UPLC-MS based metabolomics method
  publication-title: Metabolomics
  doi: 10.1007/s11306-018-1397-x
– volume: 61
  start-page: 989
  year: 2022
  ident: B115
  article-title: Metabolomics-based classification reveals subtypes of hepatocellular carcinoma
  publication-title: Mol Carcinog
  doi: 10.1002/mc.23455
– volume: 15
  start-page: 156
  year: 2019
  ident: B75
  article-title: Clinical and metabolomics analysis of hepatocellular carcinoma patients with diabetes mellitus
  publication-title: Metabolomics
  doi: 10.1007/s11306-019-1619-x
– volume: 2
  start-page: 701
  year: 2012
  ident: B89
  article-title: Differentiating hepatocellular carcinoma from hepatitis C using metabolite profiling
  publication-title: Metabolites
  doi: 10.3390/metabo2040701
– volume: 743
  start-page: 90
  year: 2012
  ident: B96
  article-title: Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis
  publication-title: Anal Chim Acta
  doi: 10.1016/j.aca.2012.07.013
– volume: 81
  start-page: 2135
  year: 2009
  ident: B62
  article-title: Cross-Platform comparison of methods for quantitative metabolomics of primary metabolism
  publication-title: Anal Chem
  doi: 10.1021/ac8022857
– volume: 43
  start-page: 120
  year: 2020
  ident: B21
  article-title: Metabolomics of lung cancer: analytical platforms and their applications
  publication-title: J Sep Sci
  doi: 10.1002/jssc.201900736
– volume: 414
  start-page: 1525
  year: 2022
  ident: B38
  article-title: 1h-Nmr-based metabolomics reveals the biomarker panel and molecular mechanism of hepatocellular carcinoma progression
  publication-title: Anal Bioanal Chem
  doi: 10.1007/s00216-021-03768-9
– volume: 30
  start-page: 37
  year: 2009
  ident: B17
  article-title: Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2009.04014.x
– volume: 86
  start-page: 277
  year: 2017
  ident: B30
  article-title: Metabolite measurement: pitfalls to avoid and practices to follow
  publication-title: Annu Rev Biochem
  doi: 10.1146/annurev-biochem-061516-044952
– start-page: S15
  year: 2017
  ident: B28
  article-title: Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine
  publication-title: Eur J Pharm Sci
  doi: 10.1016/j.ejps.2017.05.018
– volume: 76
  start-page: 2912
  year: 2016
  ident: B111
  article-title: Acetylcarnitine is a candidate diagnostic and prognostic biomarker of hepatocellular carcinoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-15-3199
– volume: 35
  start-page: 574
  year: 2016
  ident: B55
  article-title: HILIC-MS for metabolomics: an attractive and complementary approach to RPLC-MS
  publication-title: Mass Spectrom Rev
  doi: 10.1002/mas.21445
– volume: 6
  start-page: 3393
  year: 2014
  ident: B59
  article-title: Challenges of analyzing different classes of metabolites by a single analytical method
  publication-title: Bioanalysis
  doi: 10.4155/bio.14.236
– volume: 780
  start-page: 65
  year: 2013
  ident: B68
  article-title: Targeted analysis with benchtop quadrupole-orbitrap hybrid mass spectrometer: application to determination of synthetic hormones in animal urine
  publication-title: Anal Chim Acta
  doi: 10.1016/j.aca.2013.04.017
– volume: 14
  year: 2022
  ident: B101
  article-title: Metabolic reprogramming and risk stratification of hepatocellular carcinoma studied by using gas chromatography-mass spectrometry-based metabolomics
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers14010231
– volume: 67
  start-page: 358
  year: 2018
  ident: B105
  article-title: Aasld guidelines for the treatment of hepatocellular carcinoma
  publication-title: Hepatology (Baltimore, Md)
  doi: 10.1002/hep.29086
– volume: 6
  start-page: 1160
  year: 2021
  ident: B88
  article-title: LC/MS-based global metabolomic identification of serum biomarkers differentiating hepatocellular carcinoma from chronic hepatitis B and liver cirrhosis
  publication-title: ACS omega
  doi: 10.1021/acsomega.0c04259
– volume: 648
  start-page: 98
  year: 2009
  ident: B56
  article-title: Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry
  publication-title: Anal Chim Acta
  doi: 10.1016/j.aca.2009.06.033
– volume: 86
  start-page: 1246
  year: 2014
  ident: B67
  article-title: Fully-automated approach for online dried blood spot extraction and bioanalysis by two-dimensional-liquid chromatography coupled with high-resolution quadrupole time-of-flight mass spectrometry
  publication-title: Anal Chem
  doi: 10.1021/ac403672u
– volume: 7
  start-page: 1
  year: 2011
  ident: B65
  article-title: Semi-automated non-target processing in GC×GC-ms metabolomics analysis: applicability for biomedical studies
  publication-title: Metabolomics
  doi: 10.1007/s11306-010-0219-6
– volume: 13
  start-page: 3420
  year: 2014
  ident: B98
  article-title: Metabolomics study of hepatocellular carcinoma: discovery and validation of serum potential biomarkers by using capillary electrophoresis-mass spectrometry
  publication-title: J Proteome Res
  doi: 10.1021/pr500390y
– volume: 60
  start-page: 1516
  year: 2019
  ident: B49
  article-title: (1)H NMR spectroscopy quantifies visibility of lipoproteins, subclasses, and lipids at varied temperatures and pressures
  publication-title: J Lipid Res
  doi: 10.1194/jlr.M092643
– volume: 12
  year: 2022
  ident: B6
  article-title: Precision medicine for hepatocellular carcinoma: clinical perspective
  publication-title: J Pers Med
  doi: 10.3390/jpm12020149
– volume: 17
  start-page: 451
  year: 2016
  ident: B29
  article-title: Metabolomics: beyond biomarkers and towards mechanisms
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm.2016.25
– volume: 9
  start-page: 682
  year: 2020
  ident: B14
  article-title: Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)
  publication-title: Liver Cancer
  doi: 10.1159/000509424
– volume: 144
  start-page: 1066
  year: 2013
  ident: B118
  article-title: Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2013.01.054
– volume: 34
  start-page: 4030
  year: 2016
  ident: B51
  article-title: Prospective longitudinal analysis of 2-hydroxyglutarate magnetic resonance spectroscopy identifies broad clinical utility for the management of patients with idh-mutant glioma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.67.1222
– volume: 68
  start-page: 526
  year: 2018
  ident: B10
  article-title: Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2017.09.016
– volume: 13
  year: 2021
  ident: B37
  article-title: Den-induced rat model reproduces key features of human hepatocellular carcinoma
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13194981
– volume: 12
  start-page: 2914
  year: 2013
  ident: B74
  article-title: Metabolomics as a potential new approach for investigating human reproductive disorders
  publication-title: J Proteome Res
  doi: 10.1021/pr400204q
– volume: 16
  start-page: 589
  year: 2019
  ident: B8
  article-title: A global view of hepatocellular carcinoma: trends, risk, prevention and management
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/s41575-019-0186-y
– volume: 39
  start-page: 845
  year: 2004
  ident: B69
  article-title: Triple quadrupole linear ion trap mass spectrometer for the analysis of small molecules and macromolecules
  publication-title: J Mass Spectrom
  doi: 10.1002/jms.659
– volume: 14
  start-page: 203
  year: 2017
  ident: B103
  article-title: Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/nrgastro.2016.193
– volume: 18
  start-page: 6714
  year: 2012
  ident: B100
  article-title: Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-1099
– volume: 154
  start-page: 1706
  year: 2018
  ident: B79
  article-title: Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2018.01.064
– volume: 14
  start-page: 906
  year: 2015
  ident: B73
  article-title: Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery
  publication-title: J Proteome Res
  doi: 10.1021/pr500973d
– volume: 41
  start-page: 1170
  year: 2015
  ident: B86
  article-title: Trends and predictors of outcomes after surgery for hepatocellular carcinoma: a nationwide population-based study in Taiwan
  publication-title: Eur J Surg Oncol
  doi: 10.1016/j.ejso.2015.04.023
– volume: 9
  start-page: 729
  year: 2022
  ident: B121
  article-title: Vitamin B6 metabolic pathway is involved in the pathogenesis of liver diseases via multi-omics analysis
  publication-title: J Hepatocell Carcinoma
  doi: 10.2147/JHC.S370255
– volume: 5
  start-page: 16101
  year: 2015
  ident: B39
  article-title: Metabolomics identifies biomarker pattern for early diagnosis of hepatocellular carcinoma: from diethylnitrosamine treated rats to patients
  publication-title: Sci Rep
  doi: 10.1038/srep16101
– volume: 135
  start-page: 658
  year: 2014
  ident: B97
  article-title: NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis
  publication-title: Int J Cancer
  doi: 10.1002/ijc.28706
– volume: 9
  start-page: 6245
  year: 2018
  ident: B108
  article-title: Determination of candidate metabolite biomarkers associated with recurrence of HCV-related hepatocellular carcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.23500
– volume: 146
  start-page: 1741
  year: 2020
  ident: B102
  article-title: Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma
  publication-title: Int J Cancer
  doi: 10.1002/ijc.32599
– volume: 391
  start-page: 1301
  year: 2018
  ident: B12
  article-title: Hepatocellular carcinoma
  publication-title: Lancet
  doi: 10.1016/s0140-6736(18)30010-2
– volume: 43
  start-page: 34
  year: 2017
  ident: B52
  article-title: The future of NMR-based metabolomics
  publication-title: Curr Opin Biotechnol
  doi: 10.1016/j.copbio.2016.08.001
– volume: 10
  year: 2020
  ident: B60
  article-title: Metabolomic biomarkers for detection, prognosis and identifying recurrence in endometrial cancer
  publication-title: Metabolites
  doi: 10.3390/metabo10080314
– volume: 26
  start-page: 4607
  year: 2020
  ident: B78
  article-title: Establishment of a pattern recognition metabolomics model for the diagnosis of hepatocellular carcinoma
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v26.i31.4607
– volume: 11
  start-page: 303
  year: 2018
  ident: B81
  article-title: Metabolomics profiles of hepatocellular carcinoma in a Korean prospective cohort: the Korean cancer prevention study-II
  publication-title: Cancer Prev Res (Phila)
  doi: 10.1158/1940-6207.CAPR-17-0249
– volume: 45
  start-page: 2347
  year: 2019
  ident: B104
  article-title: A prognostic fingerprint in liver transplantation for hepatocellular carcinoma based on plasma metabolomics profiling
  publication-title: Eur J Surg Oncol
  doi: 10.1016/j.ejso.2019.07.004
– volume: 10
  start-page: e0127299
  year: 2015
  ident: B93
  article-title: GC-MS based plasma metabolomics for identification of candidate biomarkers for hepatocellular carcinoma in egyptian cohort
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0127299
– volume: 14
  start-page: 405
  year: 2018
  ident: B80
  article-title: Tissue and plasma proteomics for early stage cancer detection
  publication-title: Molecular Omics
  doi: 10.1039/C8MO00126J
– volume: 38
  start-page: 221
  year: 2019
  ident: B23
  article-title: Metabolomics toward personalized medicine
  publication-title: Mass Spectrom Rev
  doi: 10.1002/mas.21548
– volume: 4
  start-page: 487
  year: 2012
  ident: B70
  article-title: Using high-resolution quadrupole tof technology in dmpk analyses
  publication-title: Bioanalysis
  doi: 10.4155/bio.12.14
– volume: 11
  start-page: 5914
  year: 2012
  ident: B20
  article-title: Lc-Ms based serum metabolomics for identification of hepatocellular carcinoma biomarkers in egyptian cohort
  publication-title: J Proteome Res
  doi: 10.1021/pr300673x
– volume: 151
  start-page: 2144
  year: 2022
  ident: B82
  article-title: Untargeted plasma metabolomics for risk prediction of hepatocellular carcinoma: a prospective study in two Chinese cohorts
  publication-title: Int J Cancer
  doi: 10.1002/ijc.34229
– volume: 32
  start-page: 223
  year: 2011
  ident: B110
  article-title: (1)H-NMR-based metabolomics of tumor tissue for the metabolic characterization of rat hepatocellular carcinoma formation and metastasis
  publication-title: Tumour Biol
  doi: 10.1007/s13277-010-0116-7
– volume: 246
  start-page: 64
  year: 1989
  ident: B64
  article-title: Electrospray ionization for mass spectrometry of large biomolecules
  publication-title: Science
  doi: 10.1126/science.2675315
– volume: 11
  year: 2021
  ident: B109
  article-title: Two metabolomics phenotypes of human hepatocellular carcinoma in non-alcoholic fatty liver disease according to fibrosis severity
  publication-title: Metabolites
  doi: 10.3390/metabo11010054
– volume: 171
  start-page: 358
  year: 2017
  ident: B54
  article-title: Lactate metabolism in human lung tumors
  publication-title: Cell
  doi: 10.1016/j.cell.2017.09.019
– volume: 6
  start-page: 23306
  year: 2015
  ident: B42
  article-title: Mouse models of liver cancer: progress and recommendations
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4202
– volume: 23
  year: 2022
  ident: B120
  article-title: Multi-omics analysis revealed a significant alteration of critical metabolic pathways due to sorafenib-resistance in Hep3b cell lines
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms231911975
– volume: 25
  start-page: 2279
  year: 2019
  ident: B4
  article-title: Mechanisms of hepatocellular carcinoma progression
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v25.i19.2279
– volume: 12
  year: 2020
  ident: B83
  article-title: (1)H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12010241
– volume: 36
  start-page: 115
  year: 2017
  ident: B71
  article-title: Mass spectrometric based approaches in urine metabolomics and biomarker discovery
  publication-title: Mass Spectrom Rev
  doi: 10.1002/mas.21455
– volume: 13
  start-page: 242
  year: 2015
  ident: B84
  article-title: Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort
  publication-title: BMC Med
  doi: 10.1186/s12916-015-0462-9
– volume: 404
  start-page: 1239
  year: 2012
  ident: B32
  article-title: Serum metabolomics as a novel diagnostic approach for disease: a systematic review
  publication-title: Anal Bioanal Chem
  doi: 10.1007/s00216-012-6117-1
– volume: 20
  year: 2019
  ident: B48
  article-title: Applications of in-cell NMR in structural biology and drug discovery
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms20010139
– volume: 22
  year: 2021
  ident: B7
  article-title: Metabolic spectrum of liver failure in type 2 diabetes and obesity: from nafld to nash to HCC
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22094495
– volume: 488
  start-page: 68
  year: 2019
  ident: B33
  article-title: Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2018.10.039
– volume: 71
  start-page: 333
  year: 2021
  ident: B18
  article-title: Metabolomics in cancer research and emerging applications in clinical oncology
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21670
– volume: 28
  start-page: 60
  year: 2020
  ident: B57
  article-title: Gas chromatography-mass spectrometry-based analytical strategies for fatty acid analysis in biological samples
  publication-title: J Food Drug Anal
  doi: 10.1016/j.jfda.2019.10.003
– volume: 78
  start-page: 4564
  year: 2006
  ident: B76
  article-title: Metabolic profiling of glucuronides in human urine by LC-MS/MS and partial least-squares discriminant analysis for classification and prediction of gender
  publication-title: Anal Chem
  doi: 10.1021/ac0522299
– volume: 73
  start-page: 4992
  year: 2013
  ident: B112
  article-title: Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-13-0308
– volume: 58
  start-page: 229
  year: 2013
  ident: B117
  article-title: Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification
  publication-title: Hepatology (Baltimore, Md)
  doi: 10.1002/hep.26350
– volume: 7
  start-page: 47332
  year: 2016
  ident: B19
  article-title: Plasma metabolomic analysis of human hepatocellular carcinoma: diagnostic and therapeutic study
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.10119
– volume: 61
  start-page: 1137
  year: 1990
  ident: B44
  article-title: Tgf alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas
  publication-title: Cell
  doi: 10.1016/0092-8674(90)90076-Q
– volume: 24
  start-page: 611
  year: 2020
  ident: B13
  article-title: Surveillance for hepatocellular carcinoma
  publication-title: Clin Liver Dis
  doi: 10.1016/j.cld.2020.07.013
– volume: 96
  start-page: 1023
  year: 2002
  ident: B50
  article-title: Biochemical characterization of pediatric brain tumors by using in vivo and ex vivo magnetic resonance spectroscopy
  publication-title: J Neurosurg
  doi: 10.3171/jns.2002.96.6.1023
– volume: 5
  start-page: 317
  year: 2019
  ident: B91
  article-title: Profiling of plasma metabolomics in patients with hepatitis C-related liver cirrhosis and hepatocellular carcinoma
  publication-title: Clin Exp Hepatol
  doi: 10.5114/ceh.2019.89478
– volume: 29
  start-page: 551
  year: 2011
  ident: B35
  article-title: Urine metabolomics for kidney cancer detection and biomarker discovery
  publication-title: Urol Oncol
  doi: 10.1016/j.urolonc.2011.05.013
– volume: 35
  start-page: 331
  year: 2016
  ident: B113
  article-title: Advanced mass spectrometry-based multi-omics technologies for exploring the pathogenesis of hepatocellular carcinoma
  publication-title: Mass Spectrom Rev
  doi: 10.1002/mas.21439
– volume: 68
  start-page: 394
  year: 2018
  ident: B1
  article-title: Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21492
– volume: 1870
  start-page: 2
  year: 2018
  ident: B25
  article-title: Applications of metabolomics to study cancer metabolism
  publication-title: Biochim Biophys Acta Rev Cancer
  doi: 10.1016/j.bbcan.2018.04.009
– volume: 45
  start-page: 42
  year: 2007
  ident: B116
  article-title: Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
  publication-title: Hepatology (Baltimore, Md)
  doi: 10.1002/hep.21467
– volume: 34
  start-page: 1428
  year: 2014
  ident: B90
  article-title: Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS
  publication-title: Liver Int
  doi: 10.1111/liv.12541
– volume: 31
  start-page: 105
  year: 2020
  ident: B53
  article-title: Hyperpolarized MRI of human prostate cancer reveals increased lactate with tumor grade driven by monocarboxylate transporter 1
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2019.08.024
– volume: 19
  start-page: 3533
  year: 2020
  ident: B63
  article-title: Liquid chromatography-mass spectrometry-based nontargeted metabolomics predicts prognosis of hepatocellular carcinoma after curative resection
  publication-title: J Proteome Res
  doi: 10.1021/acs.jproteome.0c00344
– volume: 15
  start-page: 1380
  year: 2002
  ident: B47
  article-title: Analytical reproducibility in (1)H NMR-based metabonomic urinalysis
  publication-title: Chem Res Toxicol
  doi: 10.1021/tx0255774
– volume: 62
  start-page: 100143
  year: 2021
  ident: B61
  article-title: Integrated LC-MS metabolomics with dual derivatization for quantification of ffas in fecal samples of hepatocellular carcinoma patients
  publication-title: J Lipid Res
  doi: 10.1016/j.jlr.2021.100143
– volume: 13
  year: 2021
  ident: B106
  article-title: NMR-based lipid metabolite profiles to predict outcomes in patients undergoing interventional therapy for a hepatocellular carcinoma (HCC): a substudy of the SORAMIC trial
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13112787
– volume: 20
  year: 2019
  ident: B26
  article-title: The need for multi-omics biomarker signatures in precision medicine
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms20194781
– volume: 11
  year: 2019
  ident: B41
  article-title: Micrornas in animal models of hcc
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers11121906
SSID ssj0002512234
Score 2.3341033
SecondaryResourceType review_article
Snippet Hepatocellular carcinoma (HCC) remains a global health burden, and is mostly diagnosed at late and advanced stages. Currently, limited and insensitive...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1065506
SubjectTerms biomarkers
hepatocellular carcinoma
Medical Technology
metabolomics
multi-omics
precision medicine
Title Metabolomics in hepatocellular carcinoma: From biomarker discovery to precision medicine
URI https://www.ncbi.nlm.nih.gov/pubmed/36688143
https://www.proquest.com/docview/2768814604
https://pubmed.ncbi.nlm.nih.gov/PMC9845953
https://doaj.org/article/0f08bf9c1b2b4a02af9e8862991cfbef
Volume 4
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NS8MwFA_iyYsoftWPEcGbFLsk_Yg3FccQ5snBbiFJEzbY2rF1B_9732u7sYnoxWuT0vDeS36_l74PQu4S73gKsBHGgnl0UPJQS8dDmTHvk0xIF2Pu8OA96Q_F2ygebbX6wpiwpjxwI7iHyEeZ8dJ2DTNCR0x76TKg4cBrrDfO4-kLmLflTOEZjKjNuGiyZMALk6Aml2PsJGPgsCbAy5MdJKoL9v_EMr8HS26hT--IHLa0kT41yz0me644IaOBq0CHU0wsXtJJQceALVWJd_EYXEot9gkqypl-pL1FOaOYao_ROAuKubgYu_lJq5LOF22fHbr-0X5Khr3Xj5d-2HZKCK1Isio0sTdA_aSVPHYGOJqOojyPLACUBwCSgMoaiFoqZY7l642TQoMiLIf9613s-RnZL8rCXRCaWmmM4VjBAckFOIDAwXnOROo1EzYPSHctNWXbMuLYzWKqwJ1ASata0golrVpJB-R-8868KaLx6-xnVMZmJhbArh-AWajWLNRfZhGQ27UqFWwYlLwuXLlaKgYOFt57RiIg541qN5_iST3GA5LuKH1nLbsjxWRcF-WWmYhlzC__Y_FX5AC72tc3PeKa7FeLlbsB7lOZTm3mnfpS6gu1fgUb
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Metabolomics+in+hepatocellular+carcinoma%3A+From+biomarker+discovery+to+precision+medicine&rft.jtitle=Frontiers+in+medical+technology&rft.au=Wu%2C+Xingyun&rft.au=Wang%2C+Zihao&rft.au=Luo%2C+Li&rft.au=Shu%2C+Dan&rft.date=2023-01-04&rft.eissn=2673-3129&rft.volume=4&rft.spage=1065506&rft_id=info:doi/10.3389%2Ffmedt.2022.1065506&rft_id=info%3Apmid%2F36688143&rft.externalDocID=36688143
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2673-3129&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2673-3129&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2673-3129&client=summon